LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Lantheus Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$99.92+0.22 (+0.22%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2012 to 2025

61.1%+20.2 pts over 5 years

20.2%+21.4 pts over 5 years

15.2%+19.1 pts over 5 years

Compound annual growth to fiscal 2025

Per year	1 year	3 years	5 years	10 years
Revenue	+0.5%	+18.1%	+35.3%	+18.0%
Gross profit	-4.7%	+17.4%	+46.7%	+21.4%
Operating income	-32.0%	+104.8%	–	+22.0%
Net income	-25.2%	+102.6%	–	–
EPS, diluted	-21.8%	+104.3%	–	–

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	–	-4.3%	21.4%
Return on assets	–	-2.1%	11.1%
Current ratio	2.53	2.29	2.70
Debt to equity	-2.61	0.42	0.52
Net debt to EBITDA	3.03×	6.62×	0.55×
Interest coverage	2.1×	-0.4×	15.7×
Inventory turnover	9.9×	6.2×	9.0×
Capex to revenue	2.5%	0.0%	–
Diluted shares	33M	54M	68M

Return on equity split into margin, efficiency and leverage

Net margin15.2%

Asset turnover0.73×

Equity multiplier1.93×

Return on equity, FY202521.4%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	15.2%	0.73×	1.93×	21.4%
FY2024	20.4%	0.84×	1.91×	32.8%
FY2023	25.2%	0.87×	2.35×	51.7%
FY2022	3.0%	0.86×	2.40×	6.2%
FY2021	-16.8%	0.49×	1.77×	-14.6%
FY2020	-4.0%	0.53×	2.03×	-4.3%
FY2019	9.1%	0.82×	4.56×	34.1%
FY2018	11.8%	0.83×	8.74×	85.9%
FY2017	37.2%	1.04×	-7.69×	-296.5%

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LNTH.

Revenue growth2.3% · median -1.4%

Gross margin60.1% · median 54.9%

Operating margin19.4% · median -6.5%

Net margin17.7% · median -10.2%

Advertisement
300 × 250